July 22nd 2021, 12:00am
The FDA will expedite the development and review of the drug combination to treat untreated intermediate- high- and very high-risk myelodysplastic syndrome.
April 2nd 2021, 9:00pm
Previously, Vidaza alone showed poor response rates for patients with TP53-mutated, myelodysplastic syndromes and acute myeloid leukemia, but adding the novel agent eprenetapopt improved response rates and overall survival in this patient population.
December 17th 2020, 5:00am
3 Ways to Get Cancer Off Your Back
Pregnant Women With Previous or Current Cancer Diagnoses May Experience More Complications During Delivery
Navigating the Unknown of Rare Cancers
Playing With House Money: Defying Cancer Odds
